AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00551707
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prednisolone (2.7 mg)
Trial: NCT00551707
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01873950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01905735
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/2 ml of dispensing alcohol is administered every 7 day for 5 month orally.
Trial: NCT01364467
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children aged 7-11 years old will receive placebo 200 mg three times a day (TID), while children older than 12 will receive Placebo 400 mg TID.
Trial: NCT01773395
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Just prior to and immediately following the infusion of stem cells, the participant will receive medications to help prevent graft-versus-host disease (GVHD), a common complication of transplant where the donor's immune cells attack the recipient's body. The medications the participant will receive to prevent GVHD will include:~* Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.~* Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant.
Trial: NCT02016066
Drug: CR6261
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR6261 50 mg/kg solution will be administered as a single 2-hour intravenous infusion
Trial: NCT02016066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as a single 2-hour intravenous infusion
Trial: NCT01558687
Drug: Drug (including placebo)
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive cilengitide monotherapy for 2 weeks (Weeks 1 and 2); thereafter, cilengitide will be given in combination with the standard treatment regimen during Weeks 3 to 36. The standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.~Cilengitide monotherapy treatment will be given to subjects in Group A for another 10 months as maintenance treatment (Weeks 37 to 78). Subjects in Group A may continue to receive cilengitide maintenance treatment beyond 10 months (beyond Week 78) until occurrence of progressive disease (PD) or unacceptable toxicity, or withdrawal for any other reason. A 28-day safety follow-up will be performed after the last dose of cilengitide.
Trial: NCT03735979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV placebo solution
Trial: NCT02802345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00634413
Drug: Theophylline - ADC4022
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled theophylline (ADC4022) administered twice daily for 28 days
Trial: NCT00634413
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled matching placebo administered twice daily for 28 days
Trial: NCT01211691
Drug: KB004, Monoclonal Antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01817972
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50mg tablets
Trial: NCT00022516
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/day orally continuously for 1 year
Trial: NCT00022516
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.5 mg twice/day orally days 1 and 2 of every week for 1 year
Trial: NCT03237689
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Low dose hydrocortisone (10mg)
Trial: NCT03237689
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules of starch 1500 powder
Trial: NCT02366819
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02366819
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01194986
Drug: AZD5213
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002700
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002700
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002700
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002700
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002700
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002700
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002700
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00202540
Drug: S18986
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02247830
Drug: Urea cream
RxNorm normalized name: Amino Acid-Urea Cream
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Group 02: usual care + Topical Application of Urea cream. The intervention will be characterized by topical application of urea-based cream on the irradiated region three times daily throughout the period of realization of radiotherapy sessions, in addition to nursing consultation with instructional material (usual care).
Trial: NCT03239223
Drug: ABI-1968
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ABI-1968 Cream or Placebo with 4 doses administered up to 4 Cohorts
Trial: NCT02567695
Drug: GBT440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test: GBT440 300 mg capsule (high-strength) Reference: GBT440 100 mg capsule (low-strength)
Trial: NCT00499265
Drug: Serine Proteinase Inhibitor WX-671
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, daily
Trial: NCT00049764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04856761
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine was administered at a dose of 1250 mg/m² bid on 14 days of a tri-weekly cycle for 8 cycles.
Trial: NCT01665638
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Singe capsule of placebo administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
Trial: NCT00002828
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01739595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule taken one time daily for 3 months
Trial: NCT02291341
Drug: Cymbalta®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg capsule of Eli Lilly and Company
Trial: NCT02024581
Drug: 10% East Indian sandalwood oil cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A topical oil/water emulsion cream containing 10% East Indian sandalwood oil (EISO)
Trial: NCT02024581
Drug: Placebo Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A sandalwood-scented oil/water emulsion topical cream matching the appearance of the active comparator creams
Trial: NCT05828940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, over-encapuslated
Trial: NCT00003018
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m\^2/day, continuous IV, Days 1-28 of 5 week cycle
Trial: NCT00003018
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 30 mg/m\^2/day, IV, Days 1,8,15,22 of 5 week cycle
Trial: NCT01287117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
Trial: NCT01786018
Drug: Immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -3. Commence cyclosporine at 5.0 mg/kg PO Q12 hours, continue to day +50 and then taper by 5% per week until day +180.
Trial: NCT01786018
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1 15 mg Days 3, 6, 11 10 mg m2 day IV for GVHD prevention
Trial: NCT01186432
Drug: PDS 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02951598
Drug: Florbetapir F 18 PET Scan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Florbetapir F 18 positron emission tomography (PET) scan performed at baseline to confirm amyloid status. Participants who previously tested amyloid positive were exempt. No therapeutic investigational drug(s) intended to treat AD will be administered.
Trial: NCT02942498
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01954290
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline in the dose of 30ml/hr, with every 4 hourly measurements of serum osmolarity, serum sodium and potassium. Hypertonic saline will be increased by 30 ml to achieve target serum sodium of 150-160 and serum osmolarity 300-320
Trial: NCT02819596
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00984789
Drug: Norelgestromin/Ethinylestradiol (EVRA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6mg ethinylestradiol and 6mg norelgestromin
Trial: NCT01878565
Drug: Drug
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20 μg of HBV vaccine subcutaneously at day 6.
Trial: NCT01451515
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV.
Trial: NCT01451515
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV.
Trial: NCT01451515
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV, IM or IT.
Trial: NCT01451515
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO.
Trial: NCT01451515
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IT.
Trial: NCT03623750
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Eligible patients will receive a single pre-treatment of low dose of intravenous cyclophosphamide 200 mg/m2 (Day -3).
Trial: NCT02941731
Drug: HIP1403
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 6mg/mL
Trial: NCT02941731
Drug: HGP0919
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir phosphate 6mg/mL
Trial: NCT04819828
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard treatment for analgesia: oral diclofenac (75 mg/12 h) as needed.
Trial: NCT01023282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
Trial: NCT00644579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01439958
Drug: Inhalation
RxNorm normalized name: INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily inhalation for a maximum of three years.
Trial: NCT01217775
Drug: PH80
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PH80 intranasal spray 800 nanograms
Trial: NCT01217775
Drug: Placebo intranasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intranasal spray
Trial: NCT00671151
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline 100 mg bid for 3 months
Trial: NCT00091793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given at day 1, month 6, month 12 and month 18
Trial: NCT00002516
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00006812
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03271489
Drug: E2/NETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT00080327
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0mg, Once daily, 6 weeks.
Trial: NCT02557503
Drug: Oxaliplatin and fluorouracil
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin and fluorouracil by HAIC on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer after TACE
Trial: NCT00195351
Drug: tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
Trial: NCT02634515
Drug: Julphar Insulin R (soluble human insulin, biosimilar)
RxNorm normalized name: insulin, regular, human Injectable Solution [Novolin R]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: investigational insulin, Julphar Insulin R (soluble human insulin)
Trial: NCT02634515
Drug: Huminsulin® Normal (soluble human insulin, reference)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: marketed product, Huminsulin® Normal (soluble human insulin
Trial: NCT03797443
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Four escalating dose levels are planned in order to determine the MTD for Phase II~The dose level for Phase II patients will be determined following completion of the Phase 1b study based on response from 3-6 patients receiving the designated dose level of ascorbic acid.
Trial: NCT03240081
Drug: 50mcg estradiol cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of study drug nightly applied to vulvar vestibule
Trial: NCT03240081
Drug: 100mcg estradiol cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of study drug nightly
Trial: NCT03867253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT00761540
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide placebo for s.c. injection once daily: dose step 1 (3 subjects)
Trial: NCT00761540
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose step 2 (3 subjects)
Trial: NCT00761540
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (3 subjects)
Trial: NCT00729430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets taken orally once per day for 6 months
Trial: NCT02285010
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in capsule is prescribed to the patient 60 min prior to the surgery. Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed.
Trial: NCT04795180
Drug: Irrigations trough the efferent limb of loop ileostomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrigations trough the efferent limb of loop ileostomy during 4 weeks previous to ileostomy closure
Trial: NCT00152256
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablet, oral Daily for 6 months
Trial: NCT01870466
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin qd for 7 days
Trial: NCT01870466
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rosuvastatin qd for 7 days
Trial: NCT01450137
Drug: Placebo + Glucocorticoids (GCs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo every 4 weeks until week 52.
Trial: NCT01275638
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Soon after the presumptive diagnosis of severe sepsis, initial laboratory specimens were obtained within 2 hours, and the patients were randomized to treatment with prednisolone or placebo groups. The treatment groups were determined by a computer-generated randomization procedure (in a 1:1 ratio). The steroid group received prednisolone at a moderate-dose (20 mg/day). Prednisolone was given intravenously at 06.00 (10 mg) 14.00 (5 mg) and 22.00 (5 mg) for 10 days. The standard therapy group received a placebo infusion containing physiological saline solution in an identical manner. Patients and their primary physicians were blinded as to which therapy was administered.
Trial: NCT03968146
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
Trial: NCT03968146
Drug: additional Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive another dose of fentanyl 1 µg/kg 1 minute before start of skin incision.
Trial: NCT03968146
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive IV ketorolac from the postoperative second day 15 mg q 6 hours, not to exceed 5 days.
Trial: NCT03968146
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
Trial: NCT02936895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 2 days
Trial: NCT02838030
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 gr per day
Trial: NCT01208181
Drug: Etoricoxib 60 mg
RxNorm normalized name: etoricoxib 60 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet orally once daily for 6 weeks.
Trial: NCT01208181
Drug: Etoricoxib 90 mg
RxNorm normalized name: etoricoxib 90 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet orally once daily for 6 weeks.
Trial: NCT01208181
Drug: Placebo to Etoricoxib 60 mg
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet orally once daily for 6 weeks.
Trial: NCT01208181
Drug: Placebo to Etoricoxib 90 mg
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet orally once daily for 6 weeks
Trial: NCT00982722
Drug: cholecalciferol and calcium carbonate
RxNorm normalized name: calcium carbonate / cholecalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
Trial: NCT00942708
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total dose How to take:~Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-6 40 mg BID Week 7-12 40mg BID
Trial: NCT00104507
Drug: APD356
FDA approved: no
EMA approved: no
PMDA approved: no